ALS pill trial halted: what we know about SPG302's Long-Term safety
NCT ID NCT06903286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety and effectiveness of a daily oral medication called SPG302 in people with ALS who had already taken part in an earlier study. The trial was stopped early, and only 16 people were enrolled. Researchers tracked side effects, suicidal thoughts, and changes in daily function. Because ALS requires ongoing management and there is no cure, this trial aimed to control the disease rather than eliminate it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Flinders Medical Center
Adelaide, South Australia, 5042, Australia
-
Macquarie University
North Ryde, New South Wales, 2109, Australia
-
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Blood test may slash ALS diagnosis time from months to days
- Custom gene silencer takes aim at a rare form of ALS
- Could a gentle brain ZAP help ALS patients breathe easier?